Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hair | 12 | 2018 | 175 | 3.97 | Why? |
| HIV Infections | 36 | 2021 | 11620 | 2.06 | Why? |
| Anti-HIV Agents | 16 | 2021 | 2209 | 2.01 | Why? |
| Pre-Exposure Prophylaxis | 10 | 2021 | 1138 | 1.85 | Why? |
| Medication Adherence | 13 | 2021 | 1270 | 1.76 | Why? |
| Tenofovir | 9 | 2021 | 449 | 1.45 | Why? |
| Sustained Virologic Response | 3 | 2020 | 378 | 1.06 | Why? |
| Anti-Retroviral Agents | 4 | 2018 | 1099 | 0.90 | Why? |
| Antitubercular Agents | 2 | 2017 | 775 | 0.86 | Why? |
| Emtricitabine | 6 | 2021 | 202 | 0.80 | Why? |
| HIV | 5 | 2021 | 1116 | 0.72 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.67 | Why? |
| Diarylquinolines | 1 | 2017 | 90 | 0.65 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.64 | Why? |
| Glaucoma, Angle-Closure | 1 | 2017 | 46 | 0.64 | Why? |
| San Francisco | 8 | 2021 | 711 | 0.62 | Why? |
| Masks | 5 | 2021 | 8528 | 0.61 | Why? |
| Drug Utilization | 2 | 2018 | 619 | 0.59 | Why? |
| Laser Therapy | 1 | 2017 | 158 | 0.55 | Why? |
| Skilled Nursing Facilities | 2 | 2020 | 1098 | 0.55 | Why? |
| Population Health | 1 | 2021 | 504 | 0.55 | Why? |
| Sexually Transmitted Diseases | 2 | 2019 | 694 | 0.53 | Why? |
| Sex Characteristics | 1 | 2019 | 1120 | 0.44 | Why? |
| Homosexuality, Male | 3 | 2018 | 1158 | 0.41 | Why? |
| Drug Resistance, Multiple, Viral | 3 | 2018 | 37 | 0.41 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.41 | Why? |
| Viral Load | 9 | 2021 | 15850 | 0.41 | Why? |
| HIV-1 | 5 | 2021 | 3365 | 0.36 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.35 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.34 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.32 | Why? |
| Intraocular Pressure | 3 | 2018 | 276 | 0.32 | Why? |
| Atazanavir Sulfate | 2 | 2018 | 213 | 0.30 | Why? |
| Homeless Persons | 3 | 2021 | 1171 | 0.29 | Why? |
| Blood Chemical Analysis | 3 | 2018 | 541 | 0.29 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.29 | Why? |
| Antiretroviral Therapy, Highly Active | 5 | 2017 | 952 | 0.28 | Why? |
| Pharmacokinetics | 1 | 2004 | 41 | 0.27 | Why? |
| Glaucoma | 2 | 2018 | 225 | 0.27 | Why? |
| Tandem Mass Spectrometry | 2 | 2021 | 1031 | 0.26 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.25 | Why? |
| Pharmacology, Clinical | 1 | 2004 | 68 | 0.25 | Why? |
| Housing | 2 | 2021 | 1146 | 0.25 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.22 | Why? |
| Patient Navigation | 2 | 2018 | 62 | 0.22 | Why? |
| Chromatography, Liquid | 3 | 2021 | 640 | 0.21 | Why? |
| Disease Transmission, Infectious | 3 | 2018 | 9044 | 0.21 | Why? |
| Humans | 55 | 2021 | 930598 | 0.21 | Why? |
| No-Show Patients | 1 | 2020 | 94 | 0.20 | Why? |
| Tomography, Optical Coherence | 2 | 2018 | 1008 | 0.20 | Why? |
| Transgender Persons | 3 | 2018 | 322 | 0.19 | Why? |
| Sexual Partners | 3 | 2018 | 612 | 0.18 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.18 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.18 | Why? |
| Safety-net Providers | 1 | 2020 | 302 | 0.17 | Why? |
| Optic Disk | 1 | 2018 | 66 | 0.17 | Why? |
| Retinal Ganglion Cells | 1 | 2018 | 80 | 0.17 | Why? |
| Iridectomy | 1 | 2017 | 14 | 0.17 | Why? |
| Spectrometry, Mass, Electrospray Ionization | 1 | 2018 | 159 | 0.17 | Why? |
| Macula Lutea | 1 | 2018 | 87 | 0.17 | Why? |
| Iris | 1 | 2017 | 27 | 0.17 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.17 | Why? |
| Face | 1 | 2020 | 301 | 0.17 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.16 | Why? |
| Thailand | 2 | 2018 | 1155 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.15 | Why? |
| CD4 Lymphocyte Count | 3 | 2017 | 1517 | 0.15 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.15 | Why? |
| Longitudinal Studies | 4 | 2018 | 9893 | 0.15 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.14 | Why? |
| Population Dynamics | 1 | 2018 | 378 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.14 | Why? |
| Male | 26 | 2021 | 367725 | 0.14 | Why? |
| United States | 7 | 2021 | 46150 | 0.14 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.13 | Why? |
| Drug Overdose | 1 | 2021 | 583 | 0.13 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.13 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 533 | 0.13 | Why? |
| Gonorrhea | 1 | 2017 | 315 | 0.13 | Why? |
| Ventilation | 1 | 2021 | 1145 | 0.13 | Why? |
| Indonesia | 1 | 2017 | 1022 | 0.13 | Why? |
| Albuminuria | 2 | 2018 | 164 | 0.13 | Why? |
| Female | 25 | 2021 | 380317 | 0.12 | Why? |
| Vietnam | 1 | 2017 | 1665 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.12 | Why? |
| Life Expectancy | 1 | 2017 | 474 | 0.12 | Why? |
| Adolescent Behavior | 1 | 2017 | 400 | 0.11 | Why? |
| Immunization | 1 | 2020 | 2019 | 0.11 | Why? |
| Hand Disinfection | 1 | 2021 | 1671 | 0.11 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.10 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.10 | Why? |
| Adult | 19 | 2021 | 244371 | 0.10 | Why? |
| Patient Participation | 1 | 2017 | 829 | 0.10 | Why? |
| Emergency Shelter | 2 | 2021 | 202 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.10 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Pharmaceutical Preparations | 1 | 2004 | 1897 | 0.09 | Why? |
| Adolescent | 8 | 2021 | 86841 | 0.09 | Why? |
| Self Report | 2 | 2018 | 3802 | 0.09 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.09 | Why? |
| Poverty | 1 | 2020 | 2302 | 0.09 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.09 | Why? |
| Primary Health Care | 4 | 2021 | 4839 | 0.09 | Why? |
| Seroconversion | 1 | 2018 | 2515 | 0.09 | Why? |
| African Americans | 2 | 2020 | 3363 | 0.09 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.09 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.09 | Why? |
| Drug Substitution | 1 | 2011 | 385 | 0.09 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.08 | Why? |
| Unsafe Sex | 2 | 2018 | 139 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.08 | Why? |
| Pharmacists | 1 | 2017 | 1246 | 0.08 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.08 | Why? |
| Continuity of Patient Care | 1 | 2017 | 1574 | 0.08 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.08 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2008 | 309 | 0.08 | Why? |
| Loneliness | 1 | 2018 | 1766 | 0.07 | Why? |
| Kenya | 2 | 2018 | 887 | 0.07 | Why? |
| RNA, Viral | 4 | 2021 | 32276 | 0.07 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.07 | Why? |
| Child | 5 | 2021 | 70012 | 0.07 | Why? |
| Uganda | 2 | 2018 | 1057 | 0.07 | Why? |
| HIV Protease Inhibitors | 1 | 2008 | 434 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.07 | Why? |
| Europe | 1 | 2021 | 12702 | 0.07 | Why? |
| Lopinavir | 1 | 2017 | 4308 | 0.06 | Why? |
| Aged | 8 | 2021 | 215776 | 0.06 | Why? |
| Biological Availability | 1 | 2004 | 388 | 0.06 | Why? |
| Ritonavir | 1 | 2017 | 4212 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.06 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Furans | 1 | 2021 | 156 | 0.05 | Why? |
| Communication | 1 | 2017 | 5206 | 0.05 | Why? |
| Prospective Studies | 4 | 2017 | 43301 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Triazines | 1 | 2021 | 246 | 0.05 | Why? |
| Alpha-Globulins | 1 | 2018 | 18 | 0.05 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.05 | Why? |
| Metabolic Clearance Rate | 1 | 2018 | 110 | 0.04 | Why? |
| Pyrroles | 1 | 2021 | 292 | 0.04 | Why? |
| Chemistry Techniques, Analytical | 1 | 2018 | 42 | 0.04 | Why? |
| Potentially Inappropriate Medication List | 1 | 2017 | 55 | 0.04 | Why? |
| Nerve Fibers | 1 | 2018 | 73 | 0.04 | Why? |
| Medication Reconciliation | 1 | 2017 | 41 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Contact Tracing | 1 | 2017 | 8448 | 0.04 | Why? |
| Tanzania | 1 | 2018 | 294 | 0.04 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.04 | Why? |
| Zimbabwe | 1 | 2017 | 198 | 0.04 | Why? |
| Adenosine | 1 | 2021 | 509 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Motivational Interviewing | 1 | 2017 | 55 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| ROC Curve | 2 | 2018 | 6024 | 0.04 | Why? |
| Urine | 1 | 2018 | 469 | 0.04 | Why? |
| Community Health Workers | 1 | 2020 | 468 | 0.04 | Why? |
| Social Support | 2 | 2020 | 3183 | 0.04 | Why? |
| Placebos | 1 | 2018 | 629 | 0.04 | Why? |
| Proteinuria | 1 | 2018 | 474 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.03 | Why? |
| Syphilis | 1 | 2017 | 318 | 0.03 | Why? |
| Peru | 1 | 2017 | 1010 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2018 | 1165 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Analgesics, Opioid | 1 | 2021 | 1070 | 0.03 | Why? |
| Interviews as Topic | 1 | 2020 | 1952 | 0.03 | Why? |
| Program Development | 1 | 2017 | 1089 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.02 | Why? |
| Interpersonal Relations | 1 | 2017 | 926 | 0.02 | Why? |
| Animals | 1 | 2019 | 78931 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Geriatric Assessment | 1 | 2018 | 1372 | 0.02 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.02 | Why? |
| Social Stigma | 1 | 2017 | 1049 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Sex Factors | 1 | 2004 | 11014 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.02 | Why? |
| Clinical Trials as Topic | 1 | 2004 | 7330 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Substance-Related Disorders | 1 | 2017 | 2038 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2017 | 3099 | 0.01 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.01 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
| Drug Administration Schedule | 1 | 2008 | 2324 | 0.01 | Why? |
| Depression | 2 | 2018 | 14116 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Travel | 1 | 2018 | 7220 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| India | 1 | 2011 | 11875 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Mental Health | 1 | 2018 | 15770 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2008 | 8495 | 0.01 | Why? |
| Cohort Studies | 1 | 2008 | 36005 | 0.00 | Why? |